By Momo Yamamoto, Investor Research Analyst, LSN
Epidarex Capital, a transatlantic venture capital firm, provides valuable insights on what early-stage companies need to secure financing. In a concise video, Sinclair Dunlop, Managing Partner at Epidarex Capital, explains the key factors investors consider when evaluating potential investments. Click here to view the video.
For entrepreneurs seeking funding opportunities, RESI Europe in Barcelona offers a prime platform to connect with over 250 investors and licensing partners focused on early stage companies raising seed, Series A, or Series B financing. The conference features insightful investor panels where early-stage entrepreneurs can gain direct insights from active investors in their industry.
Dunlop emphasizes the importance of proactively bridging the early-stage funding gap, stating, ” In terms of attraction, in terms of milestones that have been hit, as opposed to a company that is ready for much larger financing round, or a company that is just not ready for institutional money at this point. We would not be looking for them to have met any milestones, frankly, on the way in. Because, by definition, that is all ahead of us. But our North Star is fundamental novelty. It must be novel in a way that is obviously commercially relevant. “ This approach aligns with the RESI conference’s mission to facilitate conversations that spark early-stage deals across drugs, devices, diagnostics, and digital health.
By attending RESI Europe, entrepreneurs can leverage the opportunity to pitch their ideas, network with potential investors, and gain valuable knowledge from industry experts. The conference provides a unique platform for early-stage companies to secure the funding and partnerships necessary for success.
Next Phase Newsletter 
Leave a comment